Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line
Abstract Pancreatic ductal adenocarcinoma has a high mortality rate, with a 5-year survival rate of ~ 12%. Therefore, developing new targeted therapies is urgently needed. ONC-201, a promising candidate, is currently undergoing clinical trials. The main objective of the present work is to investigat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-00070-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850277842709905408 |
|---|---|
| author | Zsófia Szász Angéla Takács Márton Kalabay Péter Bárány Tamás Czuczi Antal Csámpai Eszter Lajkó László Kőhidai |
| author_facet | Zsófia Szász Angéla Takács Márton Kalabay Péter Bárány Tamás Czuczi Antal Csámpai Eszter Lajkó László Kőhidai |
| author_sort | Zsófia Szász |
| collection | DOAJ |
| description | Abstract Pancreatic ductal adenocarcinoma has a high mortality rate, with a 5-year survival rate of ~ 12%. Therefore, developing new targeted therapies is urgently needed. ONC-201, a promising candidate, is currently undergoing clinical trials. The main objective of the present work is to investigate the anti-tumour activity of ONC-201 and its two fluorinated analogues (TBP-134, TBP-135). The viability of two pancreatic adenocarcinoma cell lines (PANC-1, MIA PaCa-2) and three other tumour cell lines (A2058, EBC-1, COLO-205) was assessed after 72-hour treatment with drugs at 0.5, 10, and 25 µM. Significant antiproliferative effects were observed, with 0.5 µM TBP-134 achieving the highest potency, reducing cell viability to approximately 50%. None of the molecules exhibited significant cytotoxicity toward normal human dermal fibroblast cells or cardiomyocytes, indicating a selective anti-tumour profile. The analogues showed more effective results than ONC201 on PANC-1 cells (IC50: 0.35 and 1.8 µM vs. IC50: 6.1 µM, respectively). All analogues induced G2/M phase arrest followed by apoptosis in PANC-1 cells. The site of the fluorination influenced the mechanism of apoptotic action of these compounds. Overall, TBP-134 showed superior efficacy, making it a promising candidate for structural optimization within the imipridone family to develop more effective, selective treatments for pancreatic tumours. |
| format | Article |
| id | doaj-art-d932ae4a6c9f4fd3878dbde8ed0736d1 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-d932ae4a6c9f4fd3878dbde8ed0736d12025-08-20T01:49:43ZengNature PortfolioScientific Reports2045-23222025-05-0115111510.1038/s41598-025-00070-xComparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell lineZsófia Szász0Angéla Takács1Márton Kalabay2Péter Bárány3Tamás Czuczi4Antal Csámpai5Eszter Lajkó6László Kőhidai7Department of Genetics, Cell- and Immunobiology, Semmelweis UniversityDepartment of Genetics, Cell- and Immunobiology, Semmelweis UniversityDepartment of Genetics, Cell- and Immunobiology, Semmelweis UniversityDepartment of Organic Chemistry, Institute of Chemistry, Eötvös Loránd UniversityDepartment of Organic Chemistry, Institute of Chemistry, Eötvös Loránd UniversityDepartment of Organic Chemistry, Institute of Chemistry, Eötvös Loránd UniversityDepartment of Genetics, Cell- and Immunobiology, Semmelweis UniversityDepartment of Genetics, Cell- and Immunobiology, Semmelweis UniversityAbstract Pancreatic ductal adenocarcinoma has a high mortality rate, with a 5-year survival rate of ~ 12%. Therefore, developing new targeted therapies is urgently needed. ONC-201, a promising candidate, is currently undergoing clinical trials. The main objective of the present work is to investigate the anti-tumour activity of ONC-201 and its two fluorinated analogues (TBP-134, TBP-135). The viability of two pancreatic adenocarcinoma cell lines (PANC-1, MIA PaCa-2) and three other tumour cell lines (A2058, EBC-1, COLO-205) was assessed after 72-hour treatment with drugs at 0.5, 10, and 25 µM. Significant antiproliferative effects were observed, with 0.5 µM TBP-134 achieving the highest potency, reducing cell viability to approximately 50%. None of the molecules exhibited significant cytotoxicity toward normal human dermal fibroblast cells or cardiomyocytes, indicating a selective anti-tumour profile. The analogues showed more effective results than ONC201 on PANC-1 cells (IC50: 0.35 and 1.8 µM vs. IC50: 6.1 µM, respectively). All analogues induced G2/M phase arrest followed by apoptosis in PANC-1 cells. The site of the fluorination influenced the mechanism of apoptotic action of these compounds. Overall, TBP-134 showed superior efficacy, making it a promising candidate for structural optimization within the imipridone family to develop more effective, selective treatments for pancreatic tumours.https://doi.org/10.1038/s41598-025-00070-xPancreas adenocarcinomaImipridoneApoptosisONC201Drug developmentTumour selectivity |
| spellingShingle | Zsófia Szász Angéla Takács Márton Kalabay Péter Bárány Tamás Czuczi Antal Csámpai Eszter Lajkó László Kőhidai Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line Scientific Reports Pancreas adenocarcinoma Imipridone Apoptosis ONC201 Drug development Tumour selectivity |
| title | Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line |
| title_full | Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line |
| title_fullStr | Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line |
| title_full_unstemmed | Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line |
| title_short | Comparative study of the anti-tumour effects of the imipridone, ONC201 and its fluorinated analogues on pancreatic cancer cell line |
| title_sort | comparative study of the anti tumour effects of the imipridone onc201 and its fluorinated analogues on pancreatic cancer cell line |
| topic | Pancreas adenocarcinoma Imipridone Apoptosis ONC201 Drug development Tumour selectivity |
| url | https://doi.org/10.1038/s41598-025-00070-x |
| work_keys_str_mv | AT zsofiaszasz comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT angelatakacs comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT martonkalabay comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT peterbarany comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT tamasczuczi comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT antalcsampai comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT eszterlajko comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline AT laszlokohidai comparativestudyoftheantitumoureffectsoftheimipridoneonc201anditsfluorinatedanaloguesonpancreaticcancercellline |